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Abstract
Renin–angiotensin–aldosterone system inhibitors (RAASi) reduce morbidity and mortality in heart failure (HF) with reduced 
ejection fraction in a dose-dependent manner. They also have a positive impact in other cardiovascular diseases (CVDs). 
However, RAASi may induce hyperkalemia, a potentially life-threatening disorder. This risk is further increased in those with 
concomitant chronic kidney disease, diabetes mellitus, and/or in patients with hypertension. Current treatment guidelines 
recommend maximal RAASi dosing to improve clinical outcomes; however, this is often limited by the development of 
hyperkalemia. When this occurs, current guidelines recommend RAASi down-titration/interruption, which, while improving 
short-term prognosis, is associated with a negative long-term prognostic impact. At present, the European Society of 
Cardiology suggests the consideration of novel potassium binders (patiromer and sodium zirconium cyclosilicate) for the 
management of RAASi-associated hyperkalemia. Both drugs can reduce serum potassium levels and prevent recurrent 
hyperkalemia. Additionally, patiromer showed enabling of RAASi optimization in high-risk patients. Nevertheless, 
precise recommendations on the use of these drugs are lacking. Building upon current HF guideline recommendations, a 
multidisciplinary expert panel convened to design an algorithm providing practical guidance on the use of novel potassium 
binders/patiromer in patients with HF and/or other CVD. As a result of that effort, we present an evidence-based treatment 
algorithm for the management of hyperkalemia with novel potassium binders/patiromer in patients with HF and/or other CVD 
receiving RAASi, including the necessary monitoring to avoid induction of hypokalemia. This algorithm aims to maintain or 
up-titrate RAASi to optimized doses, while maintaining normokalemia, improved clinical outcomes, and long-term prognosis.
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Introduction
Renin–angiotensin–aldosterone system inhibitors (RAASi) 
include angiotensin-converting enzyme inhibitors, 
angiotensin II receptor blockers, mineralocorticoid 
receptor antagonists, and angiotensin receptor-neprilysin 
inhibitors. RAASi are disease-modifying drugs in 
heart failure with reduced ejection fraction and have a 
positive impact in other cardiovascular conditions [1–3]. 
However, patients with cardiovascular disease (CVD) 
receiving treatment with RAASi are at increased risk 
of hyperkalemia, a potentially life-threatening disorder 
associated with cardiac arrhythmias and sudden cardiac 
death [2].
Hyperkalemia is usually classified as mild (serum 
potassium  [K+] 5.1–5.5  mEq/L), moderate (serum  K+ 
5.6–6.0  mEq/L), or severe (serum  K+  >  6.0  mEq/L) 
[1]. In the RALES study, only serum  K+ levels above 
5.5  mEq/L were associated with an increased risk of 
mortality [4]. While normokalemia is usually described as 
a serum  K+ value of 3.5–5 mEq/L, in patients with heart 
failure (HF), chronic kidney disease (CKD), diabetes 
mellitus (DM), or a combination of these, recent data 
conclusively demonstrated a U-shaped curve of increased 
mortality associated with serum  K+ values above or below 
4.0–5.0 mEq/L [5]. Thus, while hyperkalemia is of concern, 
over-correction of this condition (serum  K+  < 4.0 mEq/L) 
should be avoided at all costs in this patient group.
Incidence of hyperkalemia in patients with CVD 
receiving RAASi in real-world clinical practice has been 
shown to exceed that observed in clinical trials [6]. The 
risk of RAASi-induced hyperkalemia is particularly high 
in patients with HF and concomitant CKD and/or DM 
[3, 5]. Approximately 50% of these patients experience 
two or more recurrences of hyperkalemia within 1 year 
[2]. In this high-risk patient population, even mild 
hyperkalemia has been independently associated with a 
significantly increased risk of mortality [5]. Thus, while 
RAASi represent life-saving therapy, their use also poses 
a therapeutic dilemma—patients who benefit most from 
these treatments are typically those at the greatest risk of 
associated, severe hyperkalemic events [7].
Maximal RAASi dosing in patients with HF is 
advocated in treatment guidelines [1] and has been shown 
to improve survival [8]. However, following an episode of 
moderate or severe hyperkalemia, guidelines recommend 
the down-titration or cessation of RAASi, respectively 
[1, 2]. Once RAASi have been withheld, they are seldom 
re-initiated [9]. Real-world evidence has demonstrated 
that, compared with maximal target doses, sub-maximal 
RAASi dosing or RAASi discontinuation in patients with 
HF are associated with worse cardio-renal outcomes and 
an increased risk of hospitalization and mortality [8, 10]. 
In summary, while RAASi therapy improves long-term 
prognosis in a dose-dependent manner, increased serum 
 K+ worsens short-term prognosis. The latter leads to 
RAASi dose reduction or withdrawal, which in turn is 
associated with worsened long-term prognosis.
Traditional options for the management of acute 
hyperkalemia are unsuitable for long-term use. However, 
two novel potassium-binding agents, patiromer and 
sodium zirconium cyclosilicate (SZC), have been 
approved recently, on the basis that they have been 
shown to normalize elevated serum  K+ levels, maintain 
normokalemia over time, and prevent recurrent 
hyperkalemia [11–14].
SZC binds potassium through exchange with sodium, 
primarily in the gastrointestinal tract. In the phase III 
HARMONIZE trial, SZC demonstrated rapid normalization 
of serum potassium in patients with hyperkalemia and 
underlying CKD and/or DM and/or congestive HF, the 
majority of whom (68.8%) were on RAASi [11]. However, 
as the mechanism of action of SZC involves sodium, edema 
was reported in 2.4% of patients in the placebo group 
compared with up to 14.3% of patients who received the 
highest dose of SZC [11], which may constitute a limitation 
in hemodynamically unstable patients with HF presenting 
with volume overload. At present, there are no clinical trial 
data available for SZC and RAASi optimization in patients 
with HF and other comorbidities.
In contrast to SZC, the mechanism of action of 
patiromer does not involve sodium. In fact, patiromer 
binds potassium in exchange for calcium, mostly in 
the colon [12, 13]. Its sodium-free nature allows use 
in patients unable to tolerate an increase in sodium 
load, including those with HF and volume overload, 
hyper tension, marked edema, or CKD. Clinical 
trials of patiromer in patients with CKD and HF have 
demonstrated rapid serum  K+ normalization, reduced 
recurrent hyperkalemia, and RAASi enablement [13]. In 
the AMETHYST-DN trial, patiromer was shown to be 
effective in maintaining normal serum  K+ levels for a 
period of 1 year in patients with DM and CKD receiving 
RAASi, with low incidence of hypokalemia [12]. The 
PEARL-HF study demonstrated the efficacy and safety 
of patiromer in preventing hyperkalemia in patients with 
HF, with or without kidney disease, who were started on 
spironolactone [13]. Hypomagnesia occurred in 24% of 
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patients who received patiromer compared with 2% of 
patients who received the placebo (p = 0.001) [13], which 
highlights the need for serum magnesium monitoring in 
patients who receive this drug. Patiromer was also shown 
to enable continuation of treatment with spironolactone 
in the AMBER trial of patients with CKD and resistant 
hypertension [14]. The ongoing phase III DIAMOND 
study will evaluate the potential of patiromer to improve 
clinical outcomes in patients with HF by enabling 
long-term use of RAASi (ClinicalTrials.gov identifier: 
NCT03888066).
A recent consensus statement published by the Heart 
Failure Association (HFA) of the European Society of 
Cardiology (ESC) suggests that these novel potassium 
binders (patiromer and SZC) may be considered in 
patients with HF to manage hyperkalemia and, in 
selected circumstances, to enable the use of RAASi in 
more patients and at higher doses [15]. However, detailed 
recommendations for the use of these agents are not 
provided.
In the absence of clear guidance on the usage of these 
drugs, a multidisciplinary panel of expert physicians 
convened to develop an evidence-based algorithm to 
guide the prescription of the novel potassium binders/
patiromer in everyday clinical practice. The designation 
“novel potassium binders/patiromer” was chosen due to 
the fact that at present, amongst novel potassium binders, 
only patiromer has published data on RAASi optimization 
in patients with HF and other comorbidities. The proposed 
treatment algorithm presented herein ref lects the 
consensus opinions of all authors.
Guidance on the management of chronic 
hyperkalemia in patients with CVD receiving 
RAASi
The expert panel proposes a treatment algorithm 
for chronic hyperkalemia that builds upon the 2016 
ESC HF guidelines [1], the ESC Working Group on 
Cardiovascular Pharmacotherapy consensus on the 
management of hyperkalemia in patients with CVD 
treated with RAASi [2], and the HFA of the ESC clinical 
practice update on HF 2019 [15]. In line with these 
recommendations, the present algorithm aims to provide 
more detailed guidance with regard to the management of 
hyperkalemia, across the spectrum of severity, in patients 
with CVD treated with RAASi.
The guiding principle of the algorithm is to maintain or 
up-titrate RAASi therapy to maximum target doses in view 
of the prognostic gains achieved. In alignment with the 
aforementioned guidelines [1, 2, 15], we propose RAASi 
enablement and optimization in patients with HF and/or 
other CVD and chronic or recurrent hyperkalemia, through 
the use of approved, novel potassium-binding agents.
The algorithm details serum  K+ thresholds and 
patient profiles requiring treatment with novel potassium 
binders/patiromer (Fig. 1). Mild hyperkalemia (serum 
 K+ 5.1–5.5 mEq/L) is considered acceptable due to low 
associated risk and should not limit RAASi titration. 
However, serum  K+ levels between 5.1 – 5.5 mEq/L, with 
recurrent RAASi-associated hyperkalemia or in patients 
with HF and concomitant CKD stage 3b–4 and/or DM, 
are associated with increased mortality [5]. Similarly, 
serum  K+ levels >  5.5  mEq/L (moderate and severe 
hyperkalemia) are associated with increased mortality 
risk. Hence, the algorithm advocates the use of novel 
potassium binders/patiromer to enable RAASi titration 
for both such circumstances. In patients who experience 
severe hyperkalemia (serum  K+ > 6.0 mEq/L), RAASi 
therapy should be discontinued or reduced, and novel 
potassium binders/patiromer initiated. Following 
normalization of serum  K+ levels, crucial RAASi therapy 
should be re-initiated and titrated to maximal doses with 
close monitoring of serum  K+ levels.
Of note, every patient with a serum  K+ level 
> 5.0 mEq/L should be referred to hospital for specialist 
advice [1]; novel potassium binders should not substitute 
emergency treatment for acute episodes of hyperkalemia 
and should only be initiated once the patient is in a stable 
condition.
Following titration of RAASi to maximal doses, 
close monitoring of serum  K+ levels for hyperkalemia 
is recommended [1], the outcome of which may guide 
further treatment decisions. It is crucial to highlight that 
serial monitoring of serum  K+ is endorsed by treatment 
guidelines [1] and followed in clinical trial protocols; 
however, this may not be reflected in clinical practice 
[2], increasing the risk of arrhythmias and sudden 
cardiac death due to hyperkalemia. Following initiation 
or up-titration of a novel potassium binder, serum  K+ 
should be monitored at 48–72  h and repeated after 
1 week, 1 month, and 3–6 months. Serum magnesium 
should also be monitored for at least 1 month following 
initiation of patiromer.
In addition to maximal RAASi dosing, the expert 
panel advocates interrogation of additional causes of 
hyperkalemia in all patients, including diet, potassium 
salt substitutes, and other medications that may impair 
renal function.
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Conclusions
The goal of this treatment algorithm is to provide further 
guidance to physicians on the treatment of RAASi-
associated hyperkalemia in patients with HF and/or other 
CVD. The algorithm aims to enable maximal RAASi 
dosing, critical to achieve the greatest possible reduction in 
morbidity and mortality. Further evidence on the long-term 
benefits of patiromer in patients with HF receiving essential 
RAASi therapy is awaited from the DIAMOND trial.
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